WO2018208108A1 - 조절 t 세포에 특이적으로 존재하는 dkk1 단백질 및 그 용도 - Google Patents
조절 t 세포에 특이적으로 존재하는 dkk1 단백질 및 그 용도 Download PDFInfo
- Publication number
- WO2018208108A1 WO2018208108A1 PCT/KR2018/005398 KR2018005398W WO2018208108A1 WO 2018208108 A1 WO2018208108 A1 WO 2018208108A1 KR 2018005398 W KR2018005398 W KR 2018005398W WO 2018208108 A1 WO2018208108 A1 WO 2018208108A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dkk1
- present
- seq
- immune
- surface protein
- Prior art date
Links
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 title claims abstract description 144
- 210000003289 regulatory T cell Anatomy 0.000 title claims abstract description 80
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 title claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 82
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 82
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 78
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 29
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 claims description 126
- 230000000890 antigenic effect Effects 0.000 claims description 81
- 108010052285 Membrane Proteins Proteins 0.000 claims description 73
- 102000018697 Membrane Proteins Human genes 0.000 claims description 73
- 230000014509 gene expression Effects 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 51
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 201000011510 cancer Diseases 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 239000000523 sample Substances 0.000 claims description 26
- 108020004459 Small interfering RNA Proteins 0.000 claims description 21
- 210000000056 organ Anatomy 0.000 claims description 20
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 18
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 18
- 208000037976 chronic inflammation Diseases 0.000 claims description 18
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 18
- 208000030090 Acute Disease Diseases 0.000 claims description 16
- 208000023275 Autoimmune disease Diseases 0.000 claims description 16
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 16
- 206010052779 Transplant rejections Diseases 0.000 claims description 16
- 230000001154 acute effect Effects 0.000 claims description 16
- 208000006673 asthma Diseases 0.000 claims description 16
- 208000024908 graft versus host disease Diseases 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 206010003645 Atopy Diseases 0.000 claims description 15
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 15
- 108700011259 MicroRNAs Proteins 0.000 claims description 14
- 230000000692 anti-sense effect Effects 0.000 claims description 14
- 239000003018 immunosuppressive agent Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 11
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 11
- 230000001861 immunosuppressant effect Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 9
- 239000012190 activator Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 102100034343 Integrase Human genes 0.000 claims description 7
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 4
- 238000003127 radioimmunoassay Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 238000000018 DNA microarray Methods 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 238000000636 Northern blotting Methods 0.000 claims description 2
- 108010083644 Ribonucleases Proteins 0.000 claims description 2
- 102000006382 Ribonucleases Human genes 0.000 claims description 2
- 230000002860 competitive effect Effects 0.000 claims description 2
- 238000003795 desorption Methods 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 230000000951 immunodiffusion Effects 0.000 claims description 2
- 238000000760 immunoelectrophoresis Methods 0.000 claims description 2
- 238000012744 immunostaining Methods 0.000 claims description 2
- 238000000670 ligand binding assay Methods 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 238000001269 time-of-flight mass spectrometry Methods 0.000 claims description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 6
- 229940124597 therapeutic agent Drugs 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 44
- 239000004055 small Interfering RNA Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 22
- 239000013598 vector Substances 0.000 description 21
- 108020004999 messenger RNA Proteins 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- -1 malditol Substances 0.000 description 18
- 201000001441 melanoma Diseases 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 239000013604 expression vector Substances 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 206010005003 Bladder cancer Diseases 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 9
- 206010033128 Ovarian cancer Diseases 0.000 description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 9
- 206010060862 Prostate cancer Diseases 0.000 description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 9
- 208000005017 glioblastoma Diseases 0.000 description 9
- 210000003292 kidney cell Anatomy 0.000 description 9
- 201000007270 liver cancer Diseases 0.000 description 9
- 208000014018 liver neoplasm Diseases 0.000 description 9
- 201000005202 lung cancer Diseases 0.000 description 9
- 208000020816 lung neoplasm Diseases 0.000 description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 9
- 208000037819 metastatic cancer Diseases 0.000 description 9
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 9
- 239000002679 microRNA Substances 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 201000002528 pancreatic cancer Diseases 0.000 description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 description 9
- 201000005112 urinary bladder cancer Diseases 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 208000029742 colonic neoplasm Diseases 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 201000010536 head and neck cancer Diseases 0.000 description 7
- 208000014829 head and neck neoplasm Diseases 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- 206010017758 gastric cancer Diseases 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- 108050003627 Wnt Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 108091092584 GDNA Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 102000013814 Wnt Human genes 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 102100030091 Dickkopf-related protein 2 Human genes 0.000 description 2
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 description 2
- 102100037986 Dickkopf-related protein 4 Human genes 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101100223941 Homo sapiens DKK1 gene Proteins 0.000 description 2
- 101000864647 Homo sapiens Dickkopf-related protein 2 Proteins 0.000 description 2
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 description 2
- 101000951340 Homo sapiens Dickkopf-related protein 4 Proteins 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PVFFUHAAOKXVTK-UHFFFAOYSA-N 2-(methylamino)-4-oxopentanoic acid Chemical compound CNC(C(O)=O)CC(C)=O PVFFUHAAOKXVTK-UHFFFAOYSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 101100098985 Caenorhabditis elegans cct-3 gene Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102100021391 Cationic amino acid transporter 3 Human genes 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241001424289 Enosis Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
- 101000926206 Homo sapiens Putative glutathione hydrolase 3 proenzyme Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 102100034060 Putative glutathione hydrolase 3 proenzyme Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108091006230 SLC7A3 Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101150046206 WLS gene Proteins 0.000 description 1
- 101150109862 WNT-5A gene Proteins 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 108700020483 Wnt-5a Proteins 0.000 description 1
- 101100485097 Xenopus laevis wnt11b gene Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- WDVGLADRSBQDDY-UHFFFAOYSA-N holmium(3+);trinitrate Chemical compound [Ho+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O WDVGLADRSBQDDY-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000002602 induced regulatory T cell Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 210000002501 natural regulatory T cell Anatomy 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
Definitions
- the present invention relates to DKK1 (Dickkopf-1) proteins, antibodies specific thereto, and uses thereof, which are specifically present on the surface of regulatory T cells (Treg cells), among immune cells.
- DKK1 Dickkopf-1
- T cells are immune cells that are produced in the bone marrow and mature in the thymus, and function to regulate antibody production of B cells or to control the functions of innate immune cells.
- the T cells also called T lymphocytes, act not only as a helper for other immune cells, but also destroy direct invading substances.
- immune cells One of the most important functions of immune cells is that the immune response is suppressed against the antigenic substances that make up the self surrounding the immune cells, while the immune response is recognized and recognized for non-self antigenic substances.
- Immune cells induce no response to self antigens through developmental death, induction of mutations in receptors specific for self antigens, or inactivation of immune cells that recognize self antigens. This is called immunologic unresponsiveness or tolerance. Failure to self-tolerance induces an immune response to self antigens, which can lead to disease, which is called autoimmune disease.
- the regulatory T cells control the function of conventional T cells to induce an excessive immune response or self tolerance.
- the function and number of regulatory T cells are markedly reduced. Inability to perform their functions properly has been reported. Therefore, in patients with autoimmune diseases and chronic inflammatory diseases, returning regulatory T cells to normal levels of function and numbers may be one of the treatment methods.
- One object of the present invention is to provide a DKK1 (Dickkopf-1) protein or antigenic determinant thereof specifically present on the surface of regulatory T cells.
- DKK1 Dickkopf-1
- Another object of the present invention is to provide an antibody specific for the DKK1 protein specifically present on the surface of the regulatory T cells.
- Still another object of the present invention is to provide regulatory T cells in which DKK1 protein is expressed on the cell surface.
- Another object of the present invention is to provide a method for screening an immunosuppressant or immune activator.
- Another object of the present invention is to provide a method for diagnosing an immune related disease.
- the inventors have discovered a DKK1 (Dickkopf-1) protein that is specifically present on the surface of immune cells, in particular regulatory T cells, selected epitopes of the protein, immune cells expressing the DKK1 protein, In particular, by selectively selecting regulatory T cells and co-culturing them with effector T cells, the present inventors have found that they can inhibit the activity of effector T cells.
- DKK1 Dickkopf-1
- the DKK1 is one of the DKK family genes DKK1, DKK2, DKK3, and DKK4, and encodes a secreted protein.
- the DKK protein generally consists of 255 to 350 amino acids, and in the case of DKK1, has a size of 24 KDa to 29 KDa, and the N-terminus is present in the form of glycosylated sugar.
- the DKK1 may be represented by the amino acid sequence of SEQ ID NO: 1, and may be encoded by the nucleotide represented by SEQ ID NO: 2 (Table 1).
- dickkopf-1 (DKK-1) amino acid sequence MMALGAAGAT RVFVAMVAAA LGGHPLLGVS ATLNSVLNSN AIKNLPPPLG GAAGHPGSAV SAAPGILYPG GNKYQTIDNY QPYPCAEDEE CGTDEYCASP TRGGDAGVQI CLACRKRRKR CMRHAMCCPG NYCKNGICVS SDQNHFRGEI EETITESFGN DHSTLDGYSR RTTLSSKMYH TKGQEGSVCL RSSDCASGLC CARHFWSKIC KPVLKEGQVC TKHRRKGSHG LEIFQRCYCG EGLSCRIQKD HHQASNSSRL HTCQRH (SEQ ID NO: 1) dickkopf-1 (DKK-1) mRNA, complete cds (GenBank: AF177394.2) sequence atgatggctc tgggcgcagc gggagctacc cgggtctttg tcgcgatgg
- the DKK1 binds to a receptor stronger than a ligand such as Wnt3a in the Wnt signaling system involved in cell proliferation and wound recovery, thereby competitively inhibiting Wnt signaling, and thus, in the development of the heart, head, hands, etc. in embryonic development. It can play an important role.
- the increased secretion protein type DKK1 present in bone marrow plasma can identify osteolytic bone lesions in patients with multiple myeloma and determine the degree of cancer or bone disease. Can be used.
- the DKK1 may be present on the surface of immune cells, particularly regulatory T cells, without being secreted out of cells as in a general case. This may help immune cells function as regulatory T cells for self tolerance.
- a regulatory T extracellular surface protein of DKK1 represented by SEQ ID NO: 3 (Table 2).
- the regulatory T cell extracellular surface protein of DKK1 provided by the present invention may interact with a ligand present in effect T cells to reduce the activity of regulatory T cells.
- an antigenic epitope of DKK1 which is a surface protein of regulatory T cells, represented by any one of SEQ ID NOs: 4 to 36, is provided (Table 3).
- the "antigen determinant" is a site that binds the antibody in the antigen molecule, and means a part that can be recognized by the antibody.
- the antibody does not recognize the entire antigen molecule, but recognizes only a specific part, and even the same antigen molecule can recognize other antigenic determinant parts when the type of the antibody is different.
- the antigenic determinant is an antigenic determinant of an antibody that can effectively bind to the remaining domains even when a portion of the DKK1 protein exposed to the outside of the cell is cleaved and secreted out of the cell It includes.
- the polypeptide which is the antigenic determinant may include both a continuous or discontinuous sequence of a portion capable of binding an antibody to the DKK1 protein according to the present invention.
- polypeptide fragment which is the antigenic determinant of DKK1 which is the surface protein of the regulatory T cells provided by the present invention, may interact with a ligand present in the effect T cells to reduce the activity of the regulatory T cells.
- an extracellular surface protein of DKK1 represented by SEQ ID NO: 3 provided in the present invention, or a polynucleotide encoding the antigenic determinant of DKK1 of any one of SEQ ID NOs: 4 to 36. .
- an expression vector into which a polynucleotide provided in the present invention is inserted is provided.
- the "vector” is the nucleic acid molecule capable of transporting another nucleic acid to which a nucleic acid molecule is linked.
- a vector which refers to circular double stranded DNA into which additional DNA segments can be ligated.
- a phage vector Another type of vector is a viral vector, where additional DNA segments can be ligated into the viral genome.
- Some vectors are capable of autonomous replication in the host cell into which they are introduced (eg, bacterial vectors are episomal mammalian vectors of bacterial replication origin).
- vectors eg, non-episomal mammalian vectors
- Other vectors can enter the host cell and integrate into the genome of the host cell, thereby replicating with the host genome.
- some vectors can direct the expression of the genes to which they are linked in a working dimension.
- Such vectors are referred to herein as “recombinant expression vectors” or simply "expression vectors.”
- expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
- plasmid and vector may be used interchangeably because the plasmid is the most commonly used form of the vector.
- the expression vector in the present invention include commercially widely used pCDNA vectors, F, R1, RP1, Col, pBR322, ToL, Ti vectors; Cosmid; Phages such as lambda, lambdoid, M13, Mu, p1 P22, Q ⁇ , T-even, T2, T3, T7; It can be selected from the group consisting of plant viruses, but is not limited thereto. All expression vectors known to those skilled in the art as expression vectors can be used in the present invention, and the selection of the expression vector depends on the nature of the host cell of interest.
- the introduction of the vector into host cells can be performed by calcium phosphate transfection, viral infection, DEAE-dextran controlled transfection, lipofectamine transfection, or electroporation, but is not limited thereto.
- An introduction method suitable for the expression vector and the host cell can be selected and used.
- the vector contains one or more selection markers, but is not limited thereto, and may be selected depending on whether the product is produced using a vector that does not include the selection marker.
- the selection of the selection marker is selected by the host cell of interest, which uses methods already known to those skilled in the art and the present invention is not so limited.
- tag sequences can be inserted and fused to an expression vector.
- the tag may include, but is not limited to, a hexa-histidine tag, a hemagglutinin tag, a myc tag, or a flag tag. Any tag that facilitates purification known to those skilled in the art may be used in the present invention.
- a host cell line transfected with the expression vector provided in the present invention.
- host cell in the present invention includes individual cells or cell cultures that may or may have been recipients of the vector (s) for incorporation of the polypeptide insert.
- Host cells include the progeny of a single host cell, which may not necessarily be exactly the same (in morphological or genomic DNA complement) as the original parent cell because of natural, accidental or intentional mutations.
- Host cells include cells transfected in vivo with the polypeptide (s) herein.
- the host cell may include cells of mammalian, plant, insect, fungal or cellular origin, for example, bacterial cells such as E. coli, Streptomyces, Salmonella typhimurium; Fungal cells such as yeast cells and peach pastoris; Insect cells such as Drozophila and Spodoptera Sf9 cells; Chinese hamster ovary cells (CHO), SP2 / 0 (mouse myeloma), human lymphoblastoid, COS, NSO (mouse myeloma), 293T, bow melanoma cells, HT-1080, BHK (Baby hamster kidney cells, Baby Hamster Kidney cells), animal cells of HEK (Human Embryonic Kidney cells) or PERC.6 (human retinal cells); Or it may be a plant cell, but is not limited thereto, any cell that can be used as a host cell line known to those skilled in the art is available.
- bacterial cells such as E. coli, Streptomy
- a regulatory T cell comprising the extracellular surface protein of the DKK1 or the antigenic determinant of the DKK1 is provided.
- the regulatory T cells expressing the extracellular surface protein of DKK1 or antigenic determinants thereof on the surface of the present invention may inhibit the cellular activity through interaction with the effect T cells and suppress an immune response.
- a pharmaceutical composition for preventing or treating an immune related disease comprising an extracellular surface protein of the DKK1 or a regulatory T cell comprising the antigenic determinant of the DKK1 as an active ingredient. do.
- Regulatory T cells comprising the extracellular surface protein of DKK1 of the present invention may inhibit their cellular activity through interaction with effect T cells and inhibit an immune response.
- regulatory T cells expressing DKK1 protein on the cell surface are immune-related diseases caused by hyperimmune reactions, for example, autoimmune diseases, graft-versus-host disease, organ transplant rejection, asthma, atopic, acute and chronic Inflammatory diseases and the like can be effectively prevented, improved or treated.
- the DKK1 extracellular surface protein or the antigenic determinant of the present invention as an active ingredient provides a pharmaceutical composition for the prevention or treatment of immune-related diseases.
- the DKK1 extracellular surface protein or antigenic determinant fragment provided by the present invention interacts with a ligand present in effect T cells to inhibit the activity of regulatory T cells, thereby effectively preventing immune related diseases, for example cancer. Can be improved or treated.
- the term "cancer” refers to or indicates a physiological condition characterized by unregulated cell growth in mammals.
- the cancer to be prevented, improved or treated may be a solid tumor composed of agglomerates caused by abnormal growth of cells in a solid organ, and according to the site of the solid organ, stomach cancer, liver cancer, Glioblastoma, ovarian cancer, colorectal cancer, head and neck cancer, bladder cancer, renal cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and the like, and preferably, but not limited to melanoma.
- a pharmaceutical composition for preventing or treating an immune related disease comprising as an active ingredient an antibody specific for the DKK1 extracellular surface protein or the antigenic determinant of the present invention.
- the DKK1 extracellular surface protein may be present on the surface of regulatory T cells.
- the antibody may inhibit the activity of regulatory T cells to effectively prevent, ameliorate or treat cancer.
- an antibody refers to a specific protein molecule directed to an antigenic site as it is known in the art.
- an antibody refers to an antibody that specifically binds to a protein of the present invention, which antibody can be cloned into an expression vector according to a conventional method to produce a protein encoded by the marker gene. Can be obtained and prepared from conventional proteins by conventional methods. Also included are partial peptides that may be made from such proteins, and the partial peptides of the present invention include at least seven amino acids, preferably nine amino acids, more preferably twelve or more amino acids.
- the form of the antibody of the present invention is not particularly limited and a part thereof is included in the antibody of the present invention and all immunoglobulin antibodies are included as long as they are polyclonal antibody, monoclonal antibody or antigen-binding. Furthermore, the antibody of this invention also contains special antibodies, such as a humanized antibody.
- Antibodies of the invention include functional fragments of antibody molecules as well as complete forms having two full length light chains and two full length heavy chains.
- a functional fragment of an antibody molecule refers to a fragment having at least antigen binding function, and includes Fab, F (ab '), F (ab') 2 and Fv.
- the antibody specifically binds to a DKK1 protein or antigenic determinant thereof expressed on the surface of regulatory T cells to inhibit the activity of regulatory T cells to effectively prevent immune-related diseases, for example cancer. Can be improved or treated.
- the cancer may be a solid tumor composed of agglomerates generated by abnormal growth of cells in a solid organ, and according to the site of the solid organ, stomach cancer, liver cancer, glioblastoma, ovarian cancer, and colon cancer , Head and neck cancer, bladder cancer, renal cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and the like, preferably may be melanoma, but is not limited thereto.
- the antibody binds specifically to a DKK1 protein or antigenic determinant thereof expressed on the surface of regulatory T cells, thereby increasing the activity of regulatory T cells.
- Disease, graft-versus-host disease, transplant rejection, asthma, atopy, acute and chronic inflammatory diseases can be effectively prevented, ameliorated or treated.
- any one selected from the group consisting of antisense oligonucleotides, siRNA, shRNA and microRNA specific to the DKK1 extracellular surface protein of the present invention or the gene encoding the antigenic determinant is effective.
- a pharmaceutical composition for immune-related diseases is provided as an ingredient.
- the "antisense oligonucleotide” is a short length DNA synthesis strand (or DNA analog) that is antisense (or complementary) to a specific DNA or RNA target, and achieves gene-specific inhibition in vivo as well as in vitro.
- Used to Antisense oligonucleotides have been proposed to prevent the expression of a protein encoded by a DNA or RNA target by binding to the target and stopping expression at the stage of transcription, translation or splicing.
- Antisense oligonucleotides have been successfully used in cell culture and animal models of disease.
- Antisense oligonucleotides as used herein include oligonucleotides having double or single stranded DNA, double or single stranded RNA, DNA / RNA hybrids, DNA and RNA analogs and base, sugar or backbone modifications. Oligonucleotides are modified by methods known in the art to increase stability and to increase resistance to nuclease degradation. These modifications include, but are not limited to, modifications to oligonucleotide backbones, modifications of sugar moieties or bases known in the art.
- siRNA small interfering RNA
- siRNA small interfering RNA
- a double stranded structure or self-complementary sense strand (sequence corresponding to the WLS mRNA sequence) and antisense strand (sequence complementary to the WLS mRNA sequence) is located opposite each other to form a double-chain -complementary
- sense strand sequence corresponding to the WLS mRNA sequence
- antisense strand sequence complementary to the WLS mRNA sequence
- siRNAs are not limited to completely paired double-stranded RNA moieties paired with RNA, but can be paired by mismatch (the corresponding base is not complementary), expansion / protrusion (there is no base corresponding to one chain), and the like. Parts that do not achieve may be included.
- the siRNA terminal structure can be either a blunt end or a sticky end as long as the expression of the WLS gene can be inhibited by RNA interference (RNAi) effect.
- RNAi RNA interference
- the cohesive end structure is possible for both 3'-end protrusion structures and 5'-end protrusion structures.
- the siRNA molecule is not limited thereto, but may have a total length of 15 to 30 bases, preferably 19 to 21 bases.
- the "shRNA (short hairpin RNA)" is a single stranded RNA having a length of 45 to 70 nucleotides, and connects 3-10 base linkers between the sense strand of the target gene siRNA sequence and the complementary antisense strand.
- microRNA regulates various biological processes such as development, differentiation, proliferation, conservation and apoptosis.
- MicroRNAs generally regulate the expression of the gene encoding the target mRNA by destabilizing the target mRNA or disrupting translation.
- Regulatory sequences useful in the expression constructs / vectors with the antisense oligonucleotides, siRNAs, shRNAs or microRNAs in the present invention are also known in the art. It may be appropriately selected from the known contents in the following.
- the antisense oligonucleotide, siRNA, shRNA or microRNA specifically binds to a gene encoding a DKK1 protein or antigenic determinants thereof expressed on the surface of regulatory T cells to inhibit their expression and immunity.
- Related diseases can, for example, effectively prevent, ameliorate or treat cancer.
- the cancer may be a solid tumor composed of agglomerates generated by abnormal growth of cells in a solid organ, and according to the site of the solid organ, stomach cancer, liver cancer, glioblastoma, ovarian cancer, and colon cancer , Head and neck cancer, bladder cancer, renal cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and the like, preferably may be melanoma, but is not limited thereto.
- the antisense oligonucleotide, siRNA, shRNA or microRNA specifically binds to the gene encoding the DKK1 protein or antigenic determinants expressed on the surface of regulatory T cells to increase their expression. Therefore, as an immune-related disease, for example, autoimmune disease, graft versus host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases can be effectively prevented, improved or treated.
- prophylaxis may include without limitation any action that blocks, suppresses or delays the symptoms of the disease using the pharmaceutical composition of the present invention.
- treatment may include without limitation any action that improves or benefits the symptoms of the disease using the pharmaceutical composition of the present invention.
- the pharmaceutical composition may be characterized in that the capsule, tablets, granules, injections, ointments, powder or beverage form, the pharmaceutical composition may be characterized in that it is intended for humans.
- the pharmaceutical composition according to the present invention may be prepared in the form of an injection and injected directly to a site where cancer or an immune disease occurs, but is not limited thereto.
- compositions of the present invention can be used in the form of oral dosage forms, such as powders, granules, capsules, tablets, aqueous suspensions, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods.
- the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers can be used as oral administration binders, suspending agents, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments, fragrances, etc.
- buffers, preservatives, analgesic Topical agents, solubilizers, isotonic agents, stabilizers and the like can be mixed and used, and for topical administration, bases, excipients, lubricants, preservatives and the like can be used.
- the formulation of the pharmaceutical composition of the present invention can be prepared in various ways by mixing with the pharmaceutically acceptable carrier as described above.
- oral administration may be in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like, in the case of injections, in unit dosage ampoules or in multiple dosage forms. have. And other solutions, suspensions, tablets, capsules, sustained release preparations and the like.
- Suitable carriers, excipients, and diluents for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like can be used.
- fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like may be further included.
- Routes of administration of the pharmaceutical compositions according to the invention are not limited to these, but are oral, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, Sublingual or rectal. Oral or parenteral release is preferred.
- parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intramuscular, intrasternal, intradural, intralesional and intracranial injection or infusion techniques.
- the pharmaceutical compositions of the invention may also be administered in the form of suppositories for rectal administration.
- the pharmaceutical compositions of the present invention vary depending on a number of factors, including the activity, age, weight, general health, sex, formulation, time of administration, route of administration, rate of release, drug combination and severity of the particular disease to be prevented or treated, of the specific compound employed.
- the dosage of the pharmaceutical composition may be appropriately selected by those skilled in the art depending on the patient's condition, weight, degree of disease, drug form, route of administration and duration, and 0.0001 to 50 mg / kg or It may be administered at 0.001 to 50 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
- the pharmaceutical composition according to the present invention may be formulated as pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions.
- the pharmaceutical composition of the present invention may be further administered in combination with other anticancer agents, thereby effectively inhibiting general cancer cell proliferation and cancer metastasis, thereby being used for the treatment of cancer.
- the anticancer agent is nitrogen mustard, imatinib, oxaliplatin, rituximab, erlotinib, neratinib, lapatinib, zefitinib, vandetanib, nirotinib, semasanib, conservinib, axitinib, cediranib , Restautinib, trastuzumab, gefitinib, bortezomib, sunitinib, carboplatin, sorafenib, bevacizumab, cisplatin, cetuximab, biscumalboom, asparaginase, tretinoin, hydroxycarba Amide, dasatinib, estramastine, gemtuzumab ozogamycin, ibritumab tucetan, heptaplatin, methylaminolevulinic acid, amsacrine, alemtuzumab,
- the pharmaceutical composition of the present invention may be further administered in combination with other immunosuppressive agents, thereby effectively inhibiting diseases due to general hyperimmune reactions.
- the immunosuppressive agents include glucocorticoids, cyclophosphamid, cyclosporin, tacrolimu, rapamycin, type IV PDE inhibitors (Type IV PDE inhibitors).
- type IV PDE inhibitors Type IV PDE inhibitors
- p38 kinase inhibitors, azathioprine, mycophenolate mofetil, mizoribin, methotrexate, leflunomid, and brequinamide Brequina may be used one or more selected from the group consisting of, but is not limited thereto.
- a method for preventing or treating an immune related disease comprising administering to a subject in need thereof an antibody specific for the DKK1 extracellular surface protein or the antigenic determinant of the present invention. It is about.
- the subject in need of the treatment in the present invention is an individual with an immune related disease or suspected of the symptoms, wherein one example of the immune related disease is gastric cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, two Cancer, such as cervical cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and other examples include autoimmune diseases, graft versus host disease, organ transplant rejection, asthma, atopy or Acute and chronic inflammatory diseases.
- the immune related disease is gastric cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, two Cancer, such as cervical cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and other examples include autoimmune diseases, graft versus host disease, organ transplant rejection, asthma, atopy or Acute and chronic inflammatory diseases.
- the antibody specifically binds to a DKK1 protein or antigenic determinant thereof expressed on the surface of regulatory T cells to inhibit the activity of regulatory T cells to effectively prevent immune-related diseases, for example cancer. Can be improved or treated.
- the antibody binds specifically to a DKK1 protein or antigenic determinant thereof expressed on the surface of regulatory T cells, thereby increasing the activity of regulatory T cells.
- Disease, graft-versus-host disease, transplant rejection, asthma, atopy, acute and chronic inflammatory diseases can be effectively prevented, ameliorated or treated.
- a group consisting of antisense oligonucleotides, siRNAs, shRNAs and microRNAs specific for the DKK1 extracellular surface protein of the present invention or a gene encoding the antigenic determinant to a subject in need thereof It relates to a method for preventing or treating an immune related disease, comprising the step of administering any one selected from.
- the subject in need of the treatment in the present invention is an individual with an immune related disease or suspected of the symptoms, wherein one example of the immune related disease is gastric cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, two Cancer, such as cervical cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and other examples include autoimmune diseases, graft versus host disease, organ transplant rejection, asthma, atopy or Acute and chronic inflammatory diseases.
- the immune related disease is gastric cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, two Cancer, such as cervical cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and other examples include autoimmune diseases, graft versus host disease, organ transplant rejection, asthma, atopy or Acute and chronic inflammatory diseases.
- the antisense oligonucleotide, siRNA, shRNA or microRNA specifically binds to a gene encoding a DKK1 protein or antigenic determinants thereof expressed on the surface of regulatory T cells to inhibit their expression and immunity.
- Related diseases can, for example, effectively prevent, ameliorate or treat cancer.
- the antisense oligonucleotide, siRNA, shRNA or microRNA specifically binds to the gene encoding the DKK1 protein or antigenic determinants expressed on the surface of regulatory T cells to increase their expression. Therefore, as an immune-related disease, for example, autoimmune disease, graft versus host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases can be effectively prevented, improved or treated.
- Administration in one embodiment of the invention means introducing the composition of the invention to the patient in any suitable manner, the route of administration of the composition of the invention being administered via any general route as long as it can reach the desired tissue.
- the method of treatment of the present invention may comprise administering the antibody, antisense oligonucleotide, siRNA, shRNA or microRNA in a pharmaceutically effective amount.
- the effective amount is defined as the type of disease, the severity of the disease, the type and amount of the active ingredient and other ingredients contained in the composition, the type and formulation of the patient and the age, body weight, general health condition, sex and diet, time of administration, route of administration And various factors, including the rate of secretion of the composition, the duration of treatment, and the drugs used concurrently.
- the above-mentioned administration may be administered in combination with another anticancer agent or another immunosuppressant.
- contacting a sample to be assayed with an extracellular surface protein of DKK1 or a regulatory T cell comprising the antigenic determinant (b) measuring the expression level of said extracellular surface protein or said antigenic determinant; And (c) determining that the sample is an immune activator or immunosuppressant when the level of expression of the extracellular surface protein or antigenic determinant is measured to be down or upregulated.
- a method for screening an agent or an immunosuppressant is determining that the sample is an immune activator or immunosuppressant when the level of expression of the extracellular surface protein or antigenic determinant is measured to be down or upregulated.
- the "screening" is to select a substance having a specific characteristic of interest from a candidate group consisting of various substances by a specific manipulation or evaluation method.
- the screening of the present invention is directed to immunosuppressive or immunosuppressive agents when the expression of a protein of the present invention is reduced or increased after administration of a candidate agent for the treatment of such a disease to a subject suspected of an immune related disease. It is a screening method to discriminate with an activator. Means such as molecular biological assays, digital imaging, cytological and histological examinations can be used to measure the activity of the genes and proteins of the invention on disease pathological or suspicious tissue.
- the expression level of the extracellular surface protein of the DKK1 or the antigenic determinant, the amount or activity may be carried out using an antibody capable of specifically binding to the extracellular surface protein of the DKK1 or the antigenic determinant.
- the antibody and the protein of interest in the biological sample form an antigen-antibody complex, and a method of detecting the same is used.
- the "antigen-antibody complex” means a combination of a protein antigen for identifying the presence or absence of a gene of interest in a biological sample and an antibody which recognizes the same.
- the detection of the antigen-antibody complex can be detected using methods as known in the art, such as spectroscopic, photochemical, biochemical, immunochemical, electrical, absorbing, chemical and other methods.
- a method for measuring or comparing the expression level of the protein may include protein chip analysis, immunoassay, ligand binding assay, Matrix Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry (MALDI-TOF) analysis, and SELDI-TOF.
- protein chip analysis immunoassay
- ligand binding assay ligand binding assay
- MALDI-TOF Matrix Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry
- SELDI-TOF SELDI-TOF
- contacting a sample to be analyzed with a regulatory T cell comprising the extracellular surface protein of DKK1 or a gene encoding the antigenic determinant (b) measuring the expression level of the gene; And (c) determining that the sample is an immune activator or immunosuppressant when it is determined that the expression level of the gene is reduced or upregulated. It is about.
- the expression level of the extracellular surface protein of DKK1 or the gene encoding the antigenic determinant may be performed using primers, probes or antisense nucleotides capable of specifically binding to the gene. Since the information of the extracellular surface protein of the DKK1 or the antigenic determinant and the gene encoding the same according to the present invention is known, those skilled in the art based on the primer, probe or antisense nucleotide to specifically bind to the gene encoding the protein It will be easy to design.
- the primer refers to a short nucleic acid sequence capable of forming a base pair with a complementary template with a nucleic acid sequence having a short free 3-terminal hydroxyl group and serving as a starting point for template strand copying.
- Primers can initiate DNA synthesis in the presence of four different nucleoside triphosphates and reagents for polymerization (ie, DNA polymerase or reverse transcriptase) at appropriate buffers and temperatures.
- the PCR can be performed using the sense and antisense primers of genes encoding the extracellular surface protein of DKK1 to diagnose cancer through the generation of desired products. PCR conditions, sense and antisense primer lengths can be modified based on what is known in the art.
- the probe refers to nucleic acid fragments such as RNA or DNA corresponding to short bases to hundreds of bases capable of specific binding with mRNA, and are labeled to confirm the presence or absence of specific mRNAs.
- Probes may be prepared in the form of oligonucleotide probes, single stranded DNA probes, double stranded DNA probes, RNA probes and the like.
- hybridization is performed using a probe complementary to a gene encoding an extracellular surface protein of DKK1, and cancer can be diagnosed through hybridization. Selection of suitable probes and hybridization conditions can be modified based on what is known in the art.
- Primers or probes of the invention can be synthesized chemically using phosphoramidite solid support methods, or other well known methods. Such nucleic acid sequences can also be modified using many means known in the art. Non-limiting examples of such modifications include methylation, "capsulation", substitution of one or more homologs of natural nucleotides, and modifications between nucleotides, such as uncharged linkages such as methyl phosphonate, phosphoester, Phosphoramidate, carbamate, and the like) or charged linkers (eg, phosphorothioate, phosphorodithioate, etc.).
- reverse transcriptase polymerase reaction as a method for measuring or comparing the expression level of the gene, reverse transcriptase polymerase reaction, competitive reverse transcriptase polymerase reaction, real time reverse transcriptase polymerase reaction, RNase protection assay, Northern blotting or DNA chip, etc. may be used. May be, but is not limited thereto.
- the DKK1 extracellular surface protein of the present invention or an antibody specific for the antigenic determinant is provided as an active ingredient, a diagnostic composition for an immune related disease.
- the diagnosis refers to confirming the presence or characteristic of a pathological state, and for the purpose of the present invention, the diagnosis is to confirm the onset and metastasis of gastric cancer.
- the DKK1 extracellular surface protein may be present on the surface of regulatory T cells.
- the immune-related disease can be diagnosed by measuring the expression level of the DKK1 extracellular surface protein or the antigenic determinant present on the surface of regulatory T cells using the antibody.
- the immune-related disease may be cancer, more specifically cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, Pancreatic cancer, melanoma or lung cancer, and the like, preferably may be melanoma, but is not limited thereto.
- the immune-related diseases may be autoimmune diseases, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases, but are not limited thereto.
- immune-related including any one selected from the group consisting of primers, probes and antisense nucleotides specific for the DKK1 extracellular surface protein of the present invention or the gene encoding the antigenic determinant
- a composition for diagnosing a disease including any one selected from the group consisting of primers, probes and antisense nucleotides specific for the DKK1 extracellular surface protein of the present invention or the gene encoding the antigenic determinant.
- the DKK1 extracellular surface protein may be present on the surface of regulatory T cells.
- immune-related diseases can be diagnosed by measuring the expression level of DKK1 extracellular surface protein or the gene encoding the antigenic determinant present on the surface of regulatory T cells using the antibody.
- the immune-related disease may be cancer, more specifically cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, Pancreatic cancer, melanoma or lung cancer, and the like, preferably may be melanoma, but is not limited thereto.
- the immune-related diseases may be autoimmune diseases, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases, but are not limited thereto.
- a diagnostic kit for an immune related disease comprising the diagnostic composition of the present invention.
- the "kit” means a set of compositions and accessories necessary for a specific purpose.
- the kit of the present invention is a DKK1 extracellular surface protein which is a diagnostic marker for immune related diseases such as cancer, autoimmune diseases, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases.
- the disease level can be diagnosed by checking the expression level of mRNA or a protein thereof.
- Kits of the invention include primers, probes or optionally antibodies that recognize the expression level of a diagnostic marker of an immune related disease, as well as one or more other component compositions, solutions or devices suitable for the assay. Can be.
- the expression level of the extracellular surface protein or antigenic determinant is measured by using an antibody specific for the extracellular surface protein of DKK1 or the antigenic determinant present in regulatory T cells. It provides a method of providing information about related diseases.
- the immune-related disease may be cancer, more specifically cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, Pancreatic cancer, melanoma or lung cancer, and the like, preferably may be melanoma, but is not limited thereto.
- the immune-related diseases may be autoimmune diseases, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases, but are not limited thereto.
- diagnosis of the immune-related disease in the present invention may further comprise the step of administering a therapeutic agent for the immune-related disease.
- any one selected from the group consisting of primers, probes and antisense nucleotides specific for the gene encoding the DKK1 extracellular surface protein or the antigenic determinant of the present invention in regulatory T cells By measuring the expression level of the gene to provide a method for providing information on immune-related diseases.
- the immune-related disease may be cancer, more specifically cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, Pancreatic cancer, melanoma or lung cancer, and the like, preferably may be melanoma, but is not limited thereto.
- the immune-related diseases may be autoimmune diseases, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases, but are not limited thereto.
- diagnosis of the immune-related disease in the present invention may further comprise the step of administering a therapeutic agent for the immune-related disease.
- DKK1 protein is specifically present on the surface of immune cells, especially regulatory T cells, it can be used as a new target of therapeutic agents for various immune related diseases.
- Figure 1 shows the structure of the DKK1 protein according to an embodiment of the present invention.
- Figure 2 shows the result of predicting the epitope of the antigen of the DKK1 protein according to an embodiment of the present invention.
- Figure 3 shows the results of predicting the epitope of the antigen of the DKK1 protein according to an embodiment of the present invention.
- Figure 4 shows the results of predicting the epitope of the antigen of the DKK1 protein according to an embodiment of the present invention.
- Figure 5 shows the results of predicting the epitope in the 3S8V chain X of the DKK1 protein according to an embodiment of the present invention.
- Figure 6 shows the results of predicting the epitope in the 3SOQ chain Z of the DKK1 protein according to an embodiment of the present invention.
- Figure 7 shows the results of predicting the epitope in the 5FWW chain B of the DKK1 protein according to an embodiment of the present invention.
- Figure 8 shows the results of predicting the epitope in the 5FWW chain B of the DKK1 protein according to an embodiment of the present invention.
- Figure 9 shows the expression level of mRNA according to an embodiment of the present invention.
- Figure 10 shows the expression level of mRNA according to an embodiment of the present invention.
- FIG. 11 shows the expression of DKK1 protein on the surface of regulatory T cells according to an embodiment of the present invention.
- a regulatory T extracellular surface protein of DKK1 represented by SEQ ID NO: 3 is provided.
- an antigenic epitope of DKK1 which is a surface protein of regulatory T cells, represented by any one of SEQ ID NOs: 4 to 36, is provided.
- an extracellular surface protein of DKK1 represented by SEQ ID NO: 3 provided in the present invention, or a polynucleotide encoding the antigenic determinant of DKK1 of any one of SEQ ID NOs: 4 to 36. .
- an expression vector into which a polynucleotide provided in the present invention is inserted is provided.
- a host cell line transfected with the expression vector provided in the present invention.
- a regulatory T cell comprising the extracellular surface protein of the DKK1 or the antigenic determinant of the DKK1 is provided.
- a pharmaceutical composition for preventing or treating an immune related disease comprising an extracellular surface protein of the DKK1 or a regulatory T cell comprising the antigenic determinant of the DKK1 as an active ingredient. do.
- the DKK1 extracellular surface protein or the antigenic determinant of the present invention as an active ingredient provides a pharmaceutical composition for the prevention or treatment of immune-related diseases.
- a pharmaceutical composition for preventing or treating an immune related disease comprising as an active ingredient an antibody specific for the DKK1 extracellular surface protein or the antigenic determinant of the present invention.
- any one selected from the group consisting of antisense oligonucleotides, siRNA, shRNA and microRNA specific to the DKK1 extracellular surface protein of the present invention or the gene encoding the antigenic determinant is effective.
- a pharmaceutical composition for immune-related diseases is provided as an ingredient.
- a method for preventing or treating an immune related disease comprising administering to a subject in need thereof an antibody specific for the DKK1 extracellular surface protein or the antigenic determinant of the present invention. It is about.
- a group consisting of antisense oligonucleotides, siRNAs, shRNAs and microRNAs specific for the DKK1 extracellular surface protein of the present invention or a gene encoding the antigenic determinant to a subject in need thereof It relates to a method for preventing or treating an immune related disease, comprising the step of administering any one selected from.
- contacting a sample to be assayed with an extracellular surface protein of DKK1 or a regulatory T cell comprising the antigenic determinant (b) measuring the expression level of said extracellular surface protein or said antigenic determinant; And (c) determining that the sample is an immune activator or immunosuppressant when the level of expression of the extracellular surface protein or antigenic determinant is measured to be down or upregulated.
- a method for screening an agent or an immunosuppressant is determining that the sample is an immune activator or immunosuppressant when the level of expression of the extracellular surface protein or antigenic determinant is measured to be down or upregulated.
- contacting a sample to be analyzed with a regulatory T cell comprising the extracellular surface protein of DKK1 or a gene encoding the antigenic determinant (b) measuring the expression level of the gene; And (c) determining that the sample is an immune activator or immunosuppressant when it is determined that the expression level of the gene is reduced or upregulated. It is about.
- the expression level of the extracellular surface protein or antigenic determinant is measured by using an antibody specific for the extracellular surface protein of DKK1 or the antigenic determinant present in regulatory T cells. It provides a method of providing information about related diseases.
- any one selected from the group consisting of primers, probes and antisense nucleotides specific for the gene encoding the DKK1 extracellular surface protein or the antigenic determinant of the present invention in regulatory T cells By measuring the expression level of the gene to provide a method for providing information on immune-related diseases.
- DKK1 is known to bind to LRP6, a ligand specific for it, in the form of a secreted protein, so that the amino acid structure of No. 182-266 of the C-terminal portion is important for DKK1 to bind to the ligand, thereby high DKK1 and LRP6 Because of its ability to bind, its binding plays an important role in Wnt cell signaling.
- the structure of the C-terminal protein of the DKK1 is shown in FIG.
- DKK1 protein can act as a biomarker specific for regulatory T cells.
- CD4 + T cells were isolated using magnet-activated cell sorting (MACS) through CD4 beads from the spleen of mice to which C57BL / 6 or Foxp3 and FRP were commonly expressed.
- MCS magnet-activated cell sorting
- regulatory T (CD4 + CD25 + T) cells and non-regulated T (CD4 + CD25 ⁇ T) cells were isolated using a fluorescent activated cell sorter (FACS) using a CD25 antibody.
- FACS fluorescent activated cell sorter
- Each cell and the cells differentiated in Preparation Example 1 extracted mRNA using Trizol, and genomic RNA removed gDNA by a protocol provided by a company using gDNA extraction kit (Qiagen). .
- gDNA removed mRNA was synthesized into cDNA through the BDsprint cDNA Synthesis Kit (Clonetech).
- Real time PCR was performed to quantitatively confirm the expression level of DKK1 mRNA in the cDRNA.
- the real-time polymerase chain reaction was performed by SYBR Green (Molecular Probes) using a protocol provided by the manufacturer for 3 minutes at 95 °C, 15 seconds at 61 °C, 40 cycles of 30 seconds at 72 °C, Table 4 It was performed using a primer, relative gene expression was calculated using the ⁇ CT method, normalized using HPRT, the results are shown in FIG.
- the expression of the DKK family gene and the Wnt gene in the regulatory T cells was hardly confirmed, but the expression of the DKK1 gene was remarkably high. It can be seen that it is very likely to be used.
- DKK1 protein can act as a biomarker specific for regulatory T cells.
- CD4 + T cells isolated as in Example 3, Treg (CD4 + RFP +) cells, na ⁇ ve T cells, and effector T cells were classified into CD62L antibody (ebioscience) and fluorescent activated cell sorter.
- CD8 + T cells B cells are separated using an antibody against CD8 ⁇ chain, an antibody against CD19, and then with or without antibodies (ebioscience) to CD3 and CD28, or CD4 + T After culturing in a condition capable of differentiating into cell subtypes, extracting mRNA in the same manner as in Example 3, confirming the expression of DKK1 mRNA, and the results are shown in FIG. 10.
- the DKK1 gene according to the present invention was higher in regulatory T cells, and in the same regulatory T cells, the group treated with antibodies to CD3 and CD28 had higher expression of DKK1, resulting in differentiation signals. However, the expression of DKK1 was higher in thymus-produced natural Tregs than induced Tregs differentiated into experimental T-cells experimentally.
- DKK1 protein Since DKK1 protein must be expressed on the surface of regulatory T cells in order to be a target of cell therapy, the target therapy can be more effectively performed. Therefore, it was confirmed whether DKK1 protein is expressed on the surface.
- Example 4 Each differentiated T cell subtype of Example 4 above was stained with anti-CD4-APC and anti DKK1-PE antibodies and DKK1 at each cell surface using a Fluorescence-Activated Cell Sorter (FACS). The expression amount of was measured and the result is shown in FIG.
- FACS Fluorescence-Activated Cell Sorter
- the present invention relates to DKK1 (Dickkopf-1) proteins, antibodies specific thereto, and uses thereof, which are specifically present on the surface of regulatory T cells (Treg cells), among immune cells.
- DKK1 Dickkopf-1
- SEQ ID NO: 36 5FWW chain B Discontinuous epitope
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
구분 | 서열정보 |
dickkopf-1 (DKK-1) 아미노산 서열 | MMALGAAGAT RVFVAMVAAA LGGHPLLGVS ATLNSVLNSN AIKNLPPPLG GAAGHPGSAV SAAPGILYPG GNKYQTIDNY QPYPCAEDEE CGTDEYCASP TRGGDAGVQI CLACRKRRKR CMRHAMCCPG NYCKNGICVS SDQNHFRGEI EETITESFGN DHSTLDGYSR RTTLSSKMYH TKGQEGSVCL RSSDCASGLC CARHFWSKIC KPVLKEGQVC TKHRRKGSHG LEIFQRCYCG EGLSCRIQKD HHQASNSSRL HTCQRH(서열번호 1) |
dickkopf-1 (DKK-1) mRNA, complete cds (GenBank: AF177394.2) 서열 | atgatggctc tgggcgcagc gggagctacc cgggtctttg tcgcgatggt agcggcggct ctcggcggcc accctctgct gggagtgagc gccaccttga actcggttct caattccaac gctatcaaga acctgccccc accgctgggc ggcgctgcgg ggcacccagg ctctgcagtc agcgccgcgc cgggaatcct gtacccgggc gggaataagt accagaccat tgacaactac cagccgtacc cgtgcgcaga ggacgaggag tgcggcactg atgagtactg cgctagtccc acccgcggag gggacgcagg cgtgcaaatc tgtctcgcct gcaggaagcg ccgaaaacgc tgcatgcgtc acgctatgtg ctgccccggg aattactgca aaaatggaat atgtgtgtct tctgatcaaa atcatttccg aggagaaatt gaggaaacca tcactgaaag ctttggtaat gatcatagca ccttggatgg gtattccaga agaaccacct tgtcttcaaa aatgtatcac accaaaggac aagaaggttc tgtttgtctc cggtcatcag actgtgcctc aggattgtgt tgtgctagac acttctggtc caagatctgt aaacctgtcc tgaaagaagg tcaagtgtgt accaagcata ggagaaaagg ctctcatgga ctagaaatat tccagcgttg ttactgtgga gaaggtctgt cttgccggat acagaaagat caccatcaag ccagtaattc ttctaggctt cacacttgtc agagacacta a(서열번호 2) |
구분 | 서열정보 |
DKK1 extracellular domain | TLNSVLNSNAIKNLPPPLGGAAGHPGSAVSAAPGILYPGGNKYQTIDNYQPYPCAEDEECGTDEYCASPTRGGDAGVQICLACRKRRKRCMRHAMCCPGNYCKNGICVSSDQNHFRGEIEETITESFGNDHSTLDGYSRRTTLSSKMYHTKGQEGSVCLRSSDCASGLCCARHFWSKICKPVLKEGQVCTKHRRKGSHGLEIFQRCYCGEGLSCRIQKDHHQASNSSRLHTCQRH(서열번호 3) |
구분 | 서열정보 |
3S2K chain C Linear epitope | RIQKRL(서열번호 4) |
3S2K chain C Linear epitope | HRRKGSHGLE IF(서열번호 5) |
3S2K chain C Linear epitope | KGQEGSVCLR SSDCASG(서열번호 6) |
3S8V chain X Linear epitope | RIQSRL(서열번호 7) |
3S8V chain X Linear epitope | HRRKGSHGLE IF(서열번호 8) |
3S8V chain X Linear epitope | GEGL(서열번호 9) |
3S8V chain X Linear epitope | QEGSVCLRSS DCASG(서열번호 10) |
3S8V chain X Linear epitope | KEGQ(서열번호 11) |
3SOQ chain Z Linear epitope | NSNAIKN(서열번호 12) |
5FWW chain B Linear epitope | RVPGASHIH(서열번호 13) |
5FWW chain B Linear epitope | GTQNWTALQG GKPCLFWNET FQHPYNTLKY PNGE(서열번호 14) |
5FWW chain B Linear epitope | KDHGNPPPLT GTSKTSNKL(서열번호 15) |
5FWW chain B Linear epitope | FSDRINQ(서열번호 16) |
5FWW chain B Linear epitope | CYVGVYWK(서열번호 17) |
5FWW chain B Linear epitope | IRDSADMVEL LDGYTHRVLA RFHGRSRPPL SFNVSLDFVI(서열번호 18) |
5FWW chain B Linear epitope | LGEHNYC(서열번호 19) |
5FWW chain B Linear epitope | FCGNNPDYWK YGE(서열번호 20) |
5FWW chain B Linear epitope | SQRFK(서열번호 21) |
5FWW chain B Linear epitope | ATGRV(서열번호 22) |
3S2K chain C Discontinuous epitope | HKGSGL(서열번호 23) |
3S2K chain C Discontinuous epitope | IQL(서열번호 24) |
3S2K chain C Discontinuous epitope | FWIF(서열번호 25) |
3S2K chain C Discontinuous epitope | EGQGEGRH(서열번호 26) |
3S2K chain C Discontinuous epitope | KGQEGSVCLR SDASG(서열번호 27) |
3S8V chain X Discontinuous epitope | IQSRL(서열번호 28) |
3S8V chain X Discontinuous epitope | HKGSGL(서열번호 29) |
3S8V chain X Discontinuous epitope | QGSVCRSD(서열번호 30) |
3S8V chain X Discontinuous epitope | FWIF(서열번호 31) |
3S8V chain X Discontinuous epitope | EGQGGLR(서열번호 32) |
3S8V chain X Discontinuous epitope | ASG(서열번호 33) |
5FWW chain B Discontinuous epitope | GTQNWTALQG GKPCLFWNET FQHPYNTLKY PNGELGEHNY CPCYVGVYWK C(서열번호 34) |
5FWW chain B Discontinuous epitope | AMYATGRVRV PGASHIHIRD SADMELDGYT HRVLARHGRS PPLSFNVSLD FVIFSDRINQ AQAVK(서열번호 35) |
5FWW chain B Discontinuous epitope | KDHGNPPPLT GTSKTSNKLF SQRFKSGYFC GNNPDYWKYG ECFGGDG(서열번호 36) |
구분 | 서열 | |
DKK1 | 정방향(forward) | 5′-GCG GCA AGA CCT ACA CCA AGA G-3′ |
역방향(reverse) | 5′-CTT TCG GTA GTG GCG GGT AAG C-3′ | |
Gapdh | 정방향(forward) | 5′-GCC TTC CGT GTT CCT ACC-3′ |
역방향(reverse) | 5′-GCC TGC TTC ACC ACC TTC-3′ | |
DKK2 | 정방향(forward) | 5′-TGG ATC ATG ACT TCC GTGACG CTT-3′ |
역방향(reverse) | 5′-GCC ATC TTG CCA TGG TCT TGG TTT-3′ | |
DKK3 | 정방향(forward) | 5′-AGA ACT CCA AGA GGC ACA GAG CAA-3′ |
역방향(reverse) | 5′-TGT TGT GAG GGA TCT GACAAG CCA-3′ | |
DKK4 | 정방향(forward) | 5′-TGG TGG TGG CTC TCC TTG-3′ |
역방향(reverse) | 5′-AGT TCC GCA CAT CCT TCT TG-3′ | |
Wnt3a | 정방향(forward) | 5′-TCG GAG ATG GTG GTA GAG AAA CAC-3' |
역방향(reverse) | 5'-AAG TTG GGT GAG GCC TCG TAG TAG-3' | |
Wnt5a | 정방향(forward) | 5'-ACA ACC TGG CAG ATG TAG CCT GTA-3' |
역방향(reverse) | 5'-CGC GCT ATC ATA CTT CTC CTT GAG-3' | |
Wnt7b | 정방향(forward) | 5'-CCC AAT GGA GAC AAA TCC CTT TAC-3' |
역방향(reverse) | 5'- GAA ACC GTT TTG AGT GTG ACT GGT-3' | |
Wnt10b | 정방향(forward) | 5'-GTT TCC GTG AGA GTG CTT TCT CCT-3' |
역방향(reverse) | 5'-TCT TGC TCA CCA CTA CCC TTC CAT-3' | |
Wnt11 | 정방향(forward) | 5'- GGG CTT CAA AGG AAA CTG ATA GGA-3' |
역방향(reverse) | 5'-CCT TGA AAG GTC AAA TGC ACA GTC-3' |
Claims (26)
- (a) DKK1(Dickkopf-1)의 세포 외 표면 단백질 또는 서열번호 4 내지 36 중 어느 하나로 표시되는 항원 결정기를 포함하는 조절 T 세포에 분석할 시료를 접촉시키는 단계;(b) 상기 세포 외 표면 단백질 또는 상기 항원 결정기의 발현 수준을 측정하는 단계; 및(c) 상기 세포 외 표면 단백질 또는 상기 항원 결정기의 발현 수준이 감소 또는 증가 조절(down or upregulation)되는 것으로 측정될 때, 상기 시료가 면역 활성화제 또는 면역 억제제임을 판별하는 단계를 포함하는 면역 활성화제 또는 면역 억제제의 스크리닝 방법.
- 제1항에 있어서,상기 세포 외 표면 단백질 또는 상기 항원 결정기의 발현 수준은 상기 세포 외 표면 단백질 또는 상기 항원 결정기에 특이적으로 결합할 수 있는 항체를 이용하여 수행되는, 스크리닝 방법.
- 제1항에 있어서,상기 DKK1의 세포 외 표면 단백질은 서열번호 3으로 표시되는, 스크리닝 방법.
- 제1항에 있어서,상기 세포 외 표면 단백질 또는 상기 항원 결정기의 발현 수준은 단백질 칩 분석, 면역측정법, 리간드 바인딩 어세이, MALDI-TOF(Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) 분석, SELDI-TOF(Sulface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry) 분석, 방사선 면역분석, 방사 면역 확산법, 오우크테로니 면역 확산법, 로케트 면역전기영동, 조직면역 염색, 보체 고정 분석법, 2차원 전기영동 분석, 액상 크로마토그래피-질량분석(liquid chromatography-Mass Spectrometry, LC-MS), LC-MS/MS(liquid chromatography-Mass Spectrometry/ Mass Spectrometry), 웨스턴 블랏 및 ELISA(enzyme linked immunosorbent assay)으로 이루어진 군에서 선택되는 방법에 의해 수행되는, 스크리닝 방법.
- (a) DKK1(Dickkopf-1)의 세포 외 표면 단백질 또는 서열번호 4 내지 36 중 어느 하나로 표시되는 항원 결정기를 코딩하는 유전자를 포함하는 조절 T 세포에 분석할 시료를 접촉시키는 단계;(b) 상기 유전자의 발현 수준을 측정하는 단계; 및(c) 상기 유전자의 발현 수준이 감소 또는 증가 조절(down or upregulation)되는 것으로 측정될 때, 상기 시료가 면역 활성화제 또는 면역 억제제임을 판별하는 단계를 포함하는 면역 활성화제 또는 면역 억제제의 스크리닝 방법.
- 제5항에 있어서,상기 유전자의 발현 수준은 상기 유전자에 특이적으로 결합할 수 있는 프라이머, 프로브 또는 안티센스 뉴클레오티드를 이용하여 수행되는, 스크리닝 방법.
- 제5항에 있어서,상기 DKK1의 세포 외 표면 단백질은 서열번호 3으로 표시되는, 스크리닝 방법.
- 제5항에 있어서,상기 유전자의 발현 수준은 역전사효소 중합효소반응, 경쟁적 역전사효소 중합효소반응, 실시간 역전사효소 중합효소반응, RNase 보호 분석법, 노던 블랏팅 및 DNA 칩으로 이루어진 군에서 선택되는 방법에 의해 수행되는, 스크리닝 방법.
- 서열번호 4 내지 36 중 어느 하나로 표시되는 DKK1(Dickkopf-1)의 항원 결정기.
- 서열번호 3으로 표시되는 DKK1(Dickkopf-1)의 세포 외 표면 단백질을 포함하는 조절 T 세포(regulatory T cell, Treg cell)를 유효 성분으로 포함하는 면역 관련 질환의 예방 또는 치료용 약학 조성물.
- 제10항에 있어서,상기 면역 관련 질환은 자가면역질환, 이식편대숙주 질환, 장기이식거부반응, 천식, 아토피 및 급성 및 만성염증 질환으로 이루어진 군에서 선택되는, 약학 조성물.
- 서열번호 4 내지 36 중 어느 하나로 표시되는 DKK1(Dickkopf-1)의 항원 결정기를 포함하는 조절 T 세포(regulatory T cell, Treg cell)를 유효 성분으로 포함하는 면역 관련 질환의 예방 또는 치료용 약학 조성물.
- 제12항에 있어서,상기 면역 관련 질환은 자가면역질환, 이식편대숙주 질환, 장기이식거부반응, 천식, 아토피 및 급성 및 만성염증 질환으로 이루어진 군에서 선택되는, 약학 조성물.
- DKK1의 세포 외 표면 단백질, 또는 서열번호 4 내지 36 중 어느 하나로 표시되는 항원 결정기에 특이적인 항체를 유효 성분으로 포함하는, 면역 관련 질환의 예방 또는 치료용 약학 조성물.
- 제14항에 있어서,상기 면역 관련 질환은 암인, 약학 조성물.
- 제14항에 있어서,상기 면역 관련 질환은 자가면역질환, 이식편대숙주 질환, 장기이식거부반응, 천식, 아토피 및 급성 및 만성염증 질환으로 이루어진 군에서 선택되는, 약학 조성물.
- DKK1의 세포 외 표면 단백질, 또는 서열번호 4 내지 36 중 어느 하나로 표시되는 항원 결정기를 코딩하는 유전자에 특이적인 안티센스 올리고뉴클레오타이드, siRNA, shRNA 및 마이크로RNA으로 이루어진 군에서 선택되는 어느 하나를 유효 성분으로 포함하는, 면역 관련 질환용 약학 조성물.
- 제17항에 있어서,상기 면역 관련 질환은 암인, 약학 조성물.
- 제17항에 있어서,상기 면역 관련 질환은 자가면역질환, 이식편대숙주 질환, 장기이식거부반응, 천식, 아토피 및 급성 및 만성염증 질환으로 이루어진 군에서 선택되는, 약학 조성물.
- DKK1 세포 외 표면 단백질 또는 서열번호 4 내지 36 중 어느 하나로 표시되는 단백질에 특이적인 항체를 포함하는, 면역 관련 질환의 진단용 조성물.
- DKK1 세포 외 표면 단백질 또는 서열번호 4 내지 36 중 어느 하나로 표시되는 항원 결정기를 코딩하는 유전자에 특이적인 프라이머, 프로브 또는 안티센스 뉴클레오티드를 포함하는, 면역 관련 질환의 진단용 조성물.
- 제20항 또는 제21항의 조성물을 포함하는 면역 관련 질환의 진단 키트.
- 조절 T 세포에 존재하는 DKK1의 세포 외 표면 단백질, 또는 서열번호 4 내지 36 중 어느 하나로 표시되는 항원 결정기에 특이적인 항체를 이용하여 상기 표면 단백질 또는 항원 결정기의 발현 수준을 측정하여 면역 관련 질환에 관한 정보를 제공하는 방법.
- 조절 T 세포에 존재하는 DKK1의 세포 외 표면 단백질, 또는 서열번호 4 내지 36 중 어느 하나로 표시되는 항원 결정기를 코딩하는 유전자에 특이적인 프라이머, 프로브 및 안티센스 뉴클레오티드으로 이루어진 군에서 선택되는 어느 하나를 이용하여 상기 유전자의 발현 수준을 측정하여 면역 관련 질환에 관한 정보를 제공하는 방법.
- 치료를 필요로 하는 대상에게 본 발명의 상기 DKK1 세포 외 표면 단백질 또는 상기 항원 결정기에 특이적인 항체를 투여하는 단계를 포함하는, 면역 관련 질환의 예방 또는 치료 방법.
- 치료를 필요로 하는 대상에게 본 발명의 상기 DKK1 세포 외 표면 단백질 또는 상기 항원 결정기를 코딩하는 유전자에 특이적인 안티센스 올리고뉴클레오타이드, siRNA, shRNA 및 마이크로RNA으로 이루어진 군에서 선택되는 어느 하나를 투여하는 단계를 포함하는, 면역 관련 질환의 예방 또는 치료 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019561863A JP2020519268A (ja) | 2017-05-10 | 2018-05-10 | 調節t細胞に特異的に存在するdkk1タンパク質およびその用途 |
CN201880031227.9A CN110799212A (zh) | 2017-05-10 | 2018-05-10 | 特异性存在于调节性t细胞中的dkk1蛋白及其用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0058336 | 2017-05-10 | ||
KR10-2017-0058337 | 2017-05-10 | ||
KR20170058336 | 2017-05-10 | ||
KR20170058337 | 2017-05-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018208108A1 true WO2018208108A1 (ko) | 2018-11-15 |
Family
ID=64105283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/005398 WO2018208108A1 (ko) | 2017-05-10 | 2018-05-10 | 조절 t 세포에 특이적으로 존재하는 dkk1 단백질 및 그 용도 |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP2020519268A (ko) |
KR (1) | KR20180123989A (ko) |
CN (1) | CN110799212A (ko) |
WO (1) | WO2018208108A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022518430A (ja) * | 2019-01-15 | 2022-03-15 | バイオニア コーポレーション | Dkk1遺伝子を標的にする二本鎖オリゴヌクレオチド、これを含む構造体及びこれを含む脱毛予防又は発毛用組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220213186A1 (en) * | 2019-03-20 | 2022-07-07 | Good T Cells, Inc. | Composition for preventing or treating brain and nervous system disease |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050084494A1 (en) * | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
US20120023600A1 (en) * | 2006-01-13 | 2012-01-26 | Janine Shulok | Compositions and methods of use for antibodies of dickkopf-1 |
-
2018
- 2018-05-10 WO PCT/KR2018/005398 patent/WO2018208108A1/ko active Application Filing
- 2018-05-10 KR KR1020180053749A patent/KR20180123989A/ko not_active Application Discontinuation
- 2018-05-10 JP JP2019561863A patent/JP2020519268A/ja active Pending
- 2018-05-10 CN CN201880031227.9A patent/CN110799212A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050084494A1 (en) * | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
US20120023600A1 (en) * | 2006-01-13 | 2012-01-26 | Janine Shulok | Compositions and methods of use for antibodies of dickkopf-1 |
Non-Patent Citations (6)
Title |
---|
CHAE, W-J. ET AL.: "Membrane-bound Dickkopf-1 in Foxp3+ Regulatory T Cells Suppresses T- cell -mediated Autoimmune Colitis", IMMUNOLOGY, vol. 152, 27 June 2017 (2017-06-27), pages 265 - 275, XP055568108 * |
DATABASE NCBI [O] 6 May 2017 (2017-05-06), "Dickkopf-related Protein 1 Precursor [Homo sapiens", XP055559631, Database accession no. NP_036374.1 * |
QIAN, J. ET AL.: "Dickkopf-1 (DKK1) Is a Widely Expressed and Potent Turnor-associated Antigen in Multiple Myeloma", BLOOD, vol. 110, no. 5, 2007, pages 1587 - 1594, XP055568100 * |
QIAN, J. ET AL.: "DKK1 as a Novel Target for Myeloma Immunotherapy", ONCOIMMUNOLOGY, vol. 1, no. 5, 2012, pages 756 - 758, XP055568094 * |
RK GERSHONK. KONDO, IMMUNOLOGY, vol. 18, 1970, pages 723 - 37 |
ZHANG, X. ET AL.: "Designation of a Novel DKK1 Multiepitope DNA Vaccine and Inhibition of Bone Loss in Collagen-induced Arthritic Mice", BIOMED RESEARCH INTERNATIONAL, vol. 2015, 2015, pages 1 - 9, XP055568092 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022518430A (ja) * | 2019-01-15 | 2022-03-15 | バイオニア コーポレーション | Dkk1遺伝子を標的にする二本鎖オリゴヌクレオチド、これを含む構造体及びこれを含む脱毛予防又は発毛用組成物 |
JP7356505B2 (ja) | 2019-01-15 | 2023-10-04 | バイオニア コーポレーション | Dkk1遺伝子を標的にする二本鎖オリゴヌクレオチド、これを含む構造体及びこれを含む脱毛予防又は発毛用組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP2020519268A (ja) | 2020-07-02 |
CN110799212A (zh) | 2020-02-14 |
KR20180123989A (ko) | 2018-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019124951A9 (en) | Gpcr heteromer inhibitors and uses thereof | |
WO2015005632A1 (ko) | Dll4와 vegf에 특이적으로 결합하는 신규 이중표적 단백질 및 이의 용도 | |
WO2020032784A1 (ko) | Hla-dr에 결합하는 키메라 항원 수용체 및 car-t 세포 | |
WO2020005003A1 (ko) | Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도 | |
WO2018208108A1 (ko) | 조절 t 세포에 특이적으로 존재하는 dkk1 단백질 및 그 용도 | |
WO2021091359A1 (ko) | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 | |
WO2023096126A1 (ko) | Mdsc 활성 저해 약물의 선별 방법 | |
WO2023277361A1 (ko) | 메소텔린 특이적 항체 및 이의 용도 | |
WO2019194586A1 (en) | Novel target for anti-cancer and immune-enhancing | |
WO2019216675A1 (ko) | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 | |
WO2016126071A1 (ko) | 키메릭 항원 수용체 전달용 ctla-4 타겟팅 트랜스-스플라이싱 라이보자임 및 이의 용도 | |
WO2022216066A1 (ko) | 암 환자의 예후 예측용 바이오마커 및 이의 용도 | |
WO2014038890A1 (ko) | Axl을 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물 | |
WO2010137770A1 (ko) | 신규한 gpcr 단백질 및 이의 용도 | |
WO2022131889A1 (ko) | Taci 단백질의 용도 | |
WO2010126279A2 (ko) | 사이토케라틴17-특이적인 인간항체 | |
WO2017061828A1 (ko) | Plrg1 (pleiotropic regulator 1) 억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 | |
WO2014021693A2 (ko) | Tm4sf5 단백질에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 | |
KR101026016B1 (ko) | T 세포 접착 분자 및 이에 대한 항체 | |
WO2017030395A1 (ko) | 비만 치료 또는 예방용 약학 조성물 | |
WO2021112640A1 (ko) | 항-tm4sf4 항체 및 이의 용도 | |
WO2023277281A1 (ko) | Cd47에 특이적인 인간화 항체 및 이를 포함하는 cd47 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2022124764A1 (ko) | Cd47에 특이적인 항체 및 이의 용도 | |
WO2017164486A1 (ko) | Tesk1 억제제를 포함하는 항암제 내성 억제용 조성물 및 tesk1 억제제의 스크리닝 방법 | |
WO2022220648A1 (ko) | Hla-dr 특이적 키메라 항원 수용체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18799358 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019561863 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018799358 Country of ref document: EP Effective date: 20191210 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18799358 Country of ref document: EP Kind code of ref document: A1 |